Pharmacovigilance Officer (RPV): Definition, Role and Outsourcing
Sommaire
The Pharmacovigilance Officer ensures that all regulatory pharmacovigilance (PV) obligations are complied with by the marketing authorization holder or operator of a medicinal product. This person is also referred to as the “pharmacovigilance contact person.”
In France, health safety relies on a stringent regulatory framework, and the Pharmacovigilance Officer is a key pillar of medicinal product safety monitoring within the pharmaceutical industry.
What is a Pharmacovigilance Officer?
The RPV is the national reference person in France identified by a company or organization operating a medicinal product (or a product referred to in Article R5121-150 of the French Public Health Code) to ensure the pharmacovigilance obligations and responsibilities incumbent upon them.
They are the French PV contact person, ensuring rigorous monitoring of products within the country, with the aim of minimizing medical risks.
The RPV is responsible for medicinal product safety following the granting of the Marketing Authorization (MA). They monitor, assess, prevent and manage the risk of adverse reactions resulting from the use of medicinal products, whether within the scope of their approved indication or outside the terms of the Marketing Authorization.
Is it mandatory to have an RPV?
In France, the appointment of a Pharmacovigilance Officer is a legal requirement set out in the French Public Health Code (Article R5121-164). Failure to comply with this requirement may result in sanctions from the French National Agency for the Safety of Medicines and Health Products (ANSM).
Countries other than France also require the appointment of an intermediary between the marketing authorization holder or operator and the local health authorities. The English term “Local Qualified Person for Pharmacovigilance (LQPPV)” is used to designate this person. In Europe, countries such as Germany, Belgium and Spain require the appointment of an LQPPV.
Some countries do not require an LQPPV as a local liaison with the relevant national competent authorities. This is the case, for example, in Ireland, Norway and Sweden.
Nevertheless, all holders of European medicinal product Marketing Authorizations are required to have a European Qualified Person Responsible for Pharmacovigilance (EU-QPPV). This person is responsible for establishing and managing the Marketing Authorization Holder’s pharmacovigilance system, also supervises the LQPPVs where applicable, and serves as the point of contact for the EMA.
What are the requirements to become a Pharmacovigilance Officer?
In France, the ANSM strictly defines the mandatory requirements that must be met to act as an RPV:
- Be a physician or pharmacist
- Reside and carry out professional activities in France
- Demonstrate experience in PV
- Be appointed before the medicinal product is placed on the market
- Ensure the continuity of PV activities, in particular by providing for a replacement system in the event of absence.
These requirements ensure that the Pharmacovigilance Officer has a precise understanding of the French regulatory framework and the ability to respond reliably to the authorities.
It should be noted that registration with the French Medical or Pharmacists’ Council is not mandatory.
Responsibilities of the Pharmacovigilance Contact Person
The Pharmacovigilance Officer plays an operational, regulatory and strategic role at the heart of the local pharmacovigilance system.
Ensuring compliance of PV activities
In France, the Pharmacovigilance Officer must ensure compliance with French health regulations throughout the country, incorporating quality and risk management requirements.
This includes ensuring compliance with PV obligations at national level, in particular:
- Reporting of Individual Case Safety Reports (ICSRs): collection and entry of suspected adverse reactions, MedDRA coding, etc.
- Signal detection and management (signal management)
- Submission of periodic safety reports (PSUR/PBRER, signal reports, etc.)
- Implementation of a local Pharmacovigilance System Master File (local PSMF), a document describing the operator’s and/or Marketing Authorization Holder’s entire PV system.
- Establishment of the PV system in France, in particular through the preparation of PV-related quality documents (SOPs, audits, etc.)
Communicating with the authorities
The appointment of a Pharmacovigilance Officer is mandatory to ensure communication with the ANSM. The RPV is responsible for official communication in the event of a signal, investigation or inspection, for example, and transmits the information required by the authorities.
In addition, the RPV is also a key contact person for the 30 Regional Pharmacovigilance Centres (CRPVs) located throughout France. They coordinate responses during national investigations and manage scientific and medical-regulatory exchanges.
Managing audits and inspections
The pharmacovigilance contact person may be involved in inspections or audits of the operator to ensure that activities comply with SOPs, European and French good pharmacovigilance practices, and the applicable legislative and regulatory provisions.
They may intervene on the following aspects:
- Presentation of the PV system (including the signal detection method, case management and reporting, etc.)
- Responses to operational questions (for example, providing justification for the medical assessment and MedDRA coding of certain cases, measures taken to ensure data security and integrity, etc.)
- Demonstration of regulatory compliance at local level
Although the RPV is the point of reference in the event of a pharmacovigilance audit or inspection, it should nevertheless be noted that the company is responsible for any findings.
Can the RPV role be outsourced?
It is entirely possible to appoint a person external to the operator while complying with French regulations. Having an in-house Pharmacovigilance Officer is not, in fact, suitable for every situation.
For laboratories whose PV activities are occasional or low-volume, outsourcing makes it possible to adjust resources as closely as possible to actual needs, without committing to a full-time position.
In a context of international expansion, outsourcing can be a strategic lever for a foreign company seeking to expand beyond its home territory. It enables the company to rely on an external local partner with expertise in national requirements (particularly those of the ANSM), thereby facilitating compliance with local regulatory requirements (such as the requirement for the RPV to reside in France). This facilitates rapid and secure compliance in the French market.
Outsourcing pharmacovigilance provides:
- Better alignment of resources with activity levels
- Access to experienced experts
- Ongoing regulatory monitoring
- Continuous updating of PV documentation
- Easier continuity of service
Are you looking for a contact person to strengthen and secure your PV system? Atessia Vigilances, a consultancy firm specializing in the regulatory and operational management of French and European health vigilance activities, can support you.
Sources :
EMA – Information on the Member States requirement for the nomination of a pharmacovigilance (PhV) contact person at national level – Human medicines requirements (consulté le 22/05/2026) : https://www.ema.europa.eu/en/documents/other/information-member-states-requirement-nomination-pharmacovigilance-phv-contact-person-national-level_en.pdf
ANSM – Bonnes pratiques de pharmacovigilance (consulté le 22/05/2026) : https://ansm.sante.fr/documents/reference/bonnes-pratiques-de-pharmacovigilance
Ingrid Pilard
Pharmaceutical Regulatory Intelligence Writer
LEARN MORE ABOUT PHARMACOVIGILANCE WITH ATESSIA VIGILANCE’S SERVICES:
OUR SUBSIDIARY SPECIALIZED IN HEALTHCARE PRODUCT RISK MANAGEMENT AND SAFETY